The top targets, EGFR, CASP3, SRC, TNF, MMP9, STAT3, and ERBB2, were selected as the core targets for molecular docking with the core compound of HQHG for ITP treatment. This evidence concerns the gene EGFR and autoimmune thrombocytopenic purpura.